Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 734-742

  Allinson, Katherine ^a,b   Kolve, Hedwig ^a   Gumbinger, Hans G ^a   Vormoor, Josef H ^a   Ehlert, Karoline ^a   Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Amphotericin B; Mycoses; Stem cell transplantation; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; RIFAMPICIN; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG INFILTRATE; MALE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; RASH; RECIPIENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHILD; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 40049084789     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm521     Document Type: Article

References (43)

1. Ritter J, Roos N. Special aspects related to invasive fungal infections in children with cancer. In: Meunier F, ed. Bailleres Clinical Infectious Diseases. London, Philadelphia, Sydney, Tokyo, Toronto, 1995; 179-204. W. B. Saunders.
2. Abbasi S, Shenep JL, Hughes WT et al. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999; 29: 1210-9.
3. Groll AH, Kurz M, Schneider W et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999; 42: 431-42.
4. Wright JA, Bradfield SM, Park JR et al. Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases. J Pediatr Hematol Oncol 2003; 25: 286-91.
5. Castagnola E, Cesaro S, Giacchino M et al. Fungal infections in children with cancer: A prospective, multicenter surveillance study. Pediatr Infect Dis J 2006; 25: 634-9.
6. Zaoutis TE, Heydon K, Chu JH et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: E711-6.
7. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42: 1584-91.
8. Offner F, Cordonnier C, Ljungman P et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-103.
9. Fukuda T, Boeckh M, Guthrie KA et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
10. Martino R, Parody R, Fukuda T et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-36.
11. Hoover M, Morgan ER, Kletzel M. Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. Med Pediatr Oncol 1997; 28: 268-73.
12. Martino R, Lopez R, Sureda A et al. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Haematologica 1997; 82: 297-304.
13. Nosari A, Oreste P, Cairoli R et al. Invasive aspergillosis in haematological malignancies: Clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001; 68: 231-6.
14. Avivi I, Oren I, Haddad N et al. Stem cell transplantation post invasive fungal infection is a feasible task. Am J Hematol 2004; 75: 6-11.
15. Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-8.
16. Kruger WH, Russmann B, de Wit M et al. Hematopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005; 113: 104-8.
17. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406-12.
18. Groll AH, Gea-Banacloche JC, Glasmacher A et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-91.
19. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
20. Denning DW, Ribaud P. Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
21. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
22. Mattei D, Mordini N, Lo Nigro C et al. Voriconazole in the management of invasive aspergillosis in two patients, with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant 2002; 30: 967-70.
23. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-8.
24. Cesaro S, Strugo L, Alaggio R et al. Voriconazole for invasive aspergillosis in oncohematological patients: A single-center pediatric experience. Support Care Cancer 2003; 11: 722-7.
25. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.
26. Walsh TJ, Driscoll TA, Arietta AC et al. Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract M-887, p. 406. American Society for Microbiology, Washington, DC, USA.
27. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8.
28. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: A randomized, prospective trial of a high loading regimen versus a standard dosing (AmBiLOAD Trial). Clin Infect Dis 2007; 44: 1289-97.
29. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
30. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
31. US Food and Drug Administration - Center for Drug Evaluation and Research. Common Terminology Criteria for Adverse Events (CTCAE) Version 3. http://www.fda.gov/cder/cancer/toxicityframe.htm
32. Groll AH, Lyman CA, Petraitiene R et al. Differential intrapulmonary disposition of voriconazole and liposomal amphotericin B in noninfected rabbits. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003 Abstract M-1256, p. 474. American Society for Microbiology, Washington, DC, USA.
33. Cornely OA, Bohme A, Reuter S et al. Efficacy of secondary antifungal prophylaxis (SP) and risk factors for breakthrough infection (IFI) after pulmonary IFI in AML patients: A multinational case registry. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2004. Abstract M-664, p. 410. American Society for Microbiology, Washington, DC, USA.
34. Paterson PJ, Seaton S, Prentice HG et al. Treatment failure in invasive aspergillosis: Susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 2003; 52 873-6.
35. Dannaoui E, Meletiadis J, Tortorano AM et al. Susceptibility testing of sequential-isolates of Aspergillus fumigatus recovered from treated patients. J Med Microbiol 2004; 53: 129-34.
36. Imhof A, Balajee SA, Fredricks DN et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-6.
37. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
38. Groll AH, Kolve H, Ehlert K et al. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004; 53: 113-4.
39. Kawazoe H, Takiguchi Y, Tanaka H et al. Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. Biol Pharm Bull 2006; 29: 2528-31.
40. Marty FM, Lowry CM, Cutler CS et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 552-9.
41. Lebrun-Vignes B, Archer VC, Diquet B et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-50.
42. Ringden O, Andstrom EE, Remberger M et al. Prophylaxis and therapy using liposomal amphotericin. B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplant 1997; 1: 124-9.
43. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.